Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331

Sierżęga, Marek; Kaczor, Marcin; Kołodziejczyk, Piotr; Kulig, Jan; Sanak, Marek; Richter, Piotr

doi:10.1038/bjc.2017.190

Cited by 90 publications

(67 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D a, b) The analysis of miR-192-5p expression shown that the level of miR-192-5p was not significantly reduced, neither in colon cancer tissues nor serum samples when compared with normal counterparts seems, the evaluation of miR-9-5p in serum of patients, suffering from gastric cancer, can be considered as a biomarker. This result was similar to some studies which monitored different microRNAs in serum samples [29,30]. The stimulatory of miR-9 in cancer progression is not only restricted to gastric cancer, since other studies also suggested that the expression of this miRNA could be altered in other human malignancies, including squamous cell carcinoma [31], breast cancer [32] and non-small-cell lung cancer [33].…”

Section: Discussionsupporting

confidence: 89%

Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients

2020

View full text Add to dashboard Cite

Objective: It has been indicated that there is a tight association between cancer and different factors, such as environment and genetics, including aberrantly expressed microRNAs. The crucial role of microRNAs in the regulation of diverse signaling pathways in gastrointestinal cancer has been established in several studies. In this study, we aimed to evaluate the expression of microRNA-9 and -192 in colon and gastric cancers. After extracting the RNA from tissues and serum samples of patients, suffering from colon and gastric cancer, cDNA was synthesized. Then by performing quantitative real-time PCR, we evaluated the expression level of miR-9-5p and miR-192-5p in collected samples.Results: Unlike to colon cancer in which the expression level of miR-9-5p remained unchanged, the relative expression of this miRNA decreased remarkably in gastric cancer (with P value < 0.05), in comparison with normal adjacent tissues. In agreement with this finding, we also found that the expression level of miR-192-5p was decreased in gastric cancer tissues, compared to normal gastric tissue. Given the reduction in the expression level of miR-9-5p and miR-192-5p in gastric cancer, it could be postulated to consider these miRNAs as promising diagnostic biomarkers.

show abstract

Section: Discussionsupporting

confidence: 89%

Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients

2020

View full text Add to dashboard Cite

show abstract

“…Many miRNAs are known to be involved in oncogenesis, tumor progression, and metastasis by targeting tumor suppressors, oncogenes, or other proteins associated with disease progression or drug resistance [4][5][6][7][8]. Differential expression of miRNAs in biological fluids of patients with different cancers and healthy donors has been previously reported by many groups [7,[9][10][11][12][13][14][15]. Other reports also showed extracellular vesicles (EVs) and cell-free nucleoprotein complexes carry distinct populations of miRNA, and the content of these miRNA pools can be used to develop promising tools for PCa screening [16,17].…”

Section: Introductionmentioning

confidence: 91%

The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms

et al. 2020

View full text Add to dashboard Cite

Prostate cancer is a global biological, medical, and social issue aggravated by the lack of reliable, highly specific, and sensitive non-invasive tests for diagnosis and staging of prostate cancer. One prospective source of biomarkers are the cell-free miRNAs present in various biological fluids. In the present study, we validated the diagnostic potential of cell-free miRNAs: miR-19b, miR-22, miR-92a, miR-378, miR-425, miR-30e, miR-31, miR-125b, miR-200b, miR-205, miR-375, and miR-660; we estimated the required sample size and the minimal miRNA set for a subsequent large-scale validation study. Relative expression of 12 miRNA combined in 31 ratios was investigated in three fractions of biological fluids (urine extracellular vesicles, clarified urine, and plasma) obtained from patients with prostate cancer (n = 10), benign prostate hyperplasia (n = 8), and healthy volunteers (n = 11). Eight of the miRNAs found in urine vesicles (miR-19b, miR-30e, miR-31, miR-92a, miR-125, miR-200, miR-205, and miR-660) showed great promise and when combined into six ratios (miR-125b/miR-30e, miR-200/miR-30e, miR-205/miR-30e, miR-31/miR-30e, miR-660/miR-30e, and miR-19b/miR-92a) could classify patients with prostate cancer, benign prostate hyperplasia, and healthy donors with 100% specificity, 100% sensitivity, and with a high degree of reliability for most donors.

show abstract

“…Many cell-free miRNAs showed altered expression patterns in different types of cancers instead of a certain type, and also similar expression between benign and malignant tumors; miR-21-5p, miR-155-5p and miR-210-3p for example, are all involved in many cancer types, but for miR-21-5p, significantly increased levels in plasma of CRC patients were observed, but it could not distinguish between malignant cancer and benign polyps [309]. In patients with NSCLC [175,[310][311][312][313], liver cancer [314] or gastric cancer [315,316], it was reportedly upregulated, but the same molecule was downregulated in patients suffering from breast cancer [188,313]. This means that the contribution of miRNAs in various types of cancers differs.…”

Section: Why Are Mirnas Not Used In Current Practice?mentioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

843

583

View full text Add to dashboard Cite

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of regulating mRNA through its degradation and adjusting protein levels. In recent years, extraordinary progress has been made in terms of identifying the origin and exact functions of miRNA, focusing on their potential use in both the research and the clinical field. This review aims at improving the current understanding of these molecules and their applicability in the medical field. A thorough analysis of the literature consulting resources available in online databases such as NCBI, PubMed, Medline, ScienceDirect, and UpToDate was performed. There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Despite present limitations, miRNAs as biomarkers for various conditions remain an impressive research field. As current techniques evolve, we anticipate that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.Biogenesis of miRNA begins in the nucleus, where the transcription of its precursor, primary miRNA or pri-miRNA takes place under the influence of RNA polymerases II and III [11,12]. The resulting molecule is a hairpin-like structure, which contains a loop at one end [11]. This primordial mi-RNA precursor that is usually made up of hundreds of nucleotides is then processed consecutively by two RNase III enzymes [13][14][15]. The first enzyme to act upon the pri-miRNA, which still resides in the nucleus, is called Drosha or DCGR8, and turns it into a new hairpin-like structure of approximately 70 nucleotides, the Precursor-miRNA or pre-miRNA. The latter is then transported to the cytoplasm, with the help of Exportin-5, where it is cleaved again by the Ago2/Dicer complex leading to the short, mature miRNA double strands [16].Further on, one of the strands, usually known as the guide strand, will be integrated into the RNA-induced silencing complex (RISC), while the other one, known as the passenger strand, is going to be degraded, even though in some occasions it has been found to be also functional [17]. In most cases, the strand that contains the less stable 5 end or a uracil at the beginning is more likely to be selected as the guide strand [18][19][20]. In those situations, where the passenger strand is not degraded and both get incorporated into the miRISC complex, the mature miRNA in the guide strand will be the dominant one [21,22].The main role of miRNA in the human body is gene regulation [23] by mediating the degradation of mRNA and also by regulating transcription and translation through canonical and non-canonical mechanisms [4]. The canonical mechanism means that the miRISC complex containing the miRNA guide strand is exerting its action by binding to the targ...

show abstract

Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331

Cited by 90 publications

References 38 publications

Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients

Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients

The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Contact Info

Product

Resources

About